Analytical Data
-
基因名
VACWR025
- Application
-
别名
28KDA protein Secretory protein 35 Short name: Protein C3 VCP
-
种属
Vaccinia virus
-
表达系统
Yeast
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P68638
-
表达区间
20-263aa
-
分子量
28.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VACWR025 is a recombinant protein derived from the Vaccinia virus, which is known for its immunogenic properties and potential applications in vaccine development and therapeutic interventions. Research into VACWR025 has gained momentum due to its ability to elicit strong immune responses, making it a candidate for inclusion in vaccine formulations against various infectious diseases. The study of VACWR025 focuses on its structure, function, and the underlying mechanisms that facilitate its interaction with the host immune system. Understanding how VACWR025 modulates immune responses can provide insights into the development of more effective vaccines, particularly in the context of viral and chronic diseases. Moreover, its recombinant nature allows for the possibility of engineering and optimizing the protein for improved efficacy and safety in immunotherapy. As researchers continue to explore the clinical implications of VACWR025, including its potential role in combating emerging infectious threats and enhancing vaccine strategies, it remains a focal point in the field of viral immunology and vaccine research.
